Active Biotech AB (publ) (ACTI.ST)
SEK 0.07
(5.23%)
SEK 0.07
(5.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -43.88 Million SEK | 20.53% |
| 2022 | -56.67 Million SEK | -16.22% |
| 2021 | -48.51 Million SEK | -56.15% |
| 2020 | -30.83 Million SEK | 0.89% |
| 2019 | -31.32 Million SEK | -6.7% |
| 2018 | -29.46 Million SEK | -515.46% |
| 2017 | -96.62 Million SEK | 116.42% |
| 2016 | -45.75 Million SEK | 74.02% |
| 2015 | -165.82 Million SEK | 23.44% |
| 2014 | -213.82 Million SEK | -9.79% |
| 2013 | -192.6 Million SEK | -28.44% |
| 2012 | -149.51 Million SEK | -99.48% |
| 2011 | -82.2 Million SEK | 66.12% |
| 2010 | -217.75 Million SEK | -6.49% |
| 2009 | -207.23 Million SEK | -15.53% |
| 2008 | -184.6 Million SEK | 8.92% |
| 2007 | -202.68 Million SEK | -97.8% |
| 2006 | -102.61 Million SEK | 6.15% |
| 2005 | -109.19 Million SEK | -153.34% |
| 2004 | 204.69 Million SEK | -40.1% |
| 2003 | 341.69 Million SEK | -1.4% |
| 2002 | 346.55 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.3 Million SEK | 14.88% |
| 2024 Q3 | -8.1 Million SEK | 25.24% |
| 2024 Q2 | -10.3 Million SEK | 0.0% |
| 2023 FY | - SEK | 20.48% |
| 2023 Q2 | -11.3 Million SEK | 5.04% |
| 2023 Q3 | -10.6 Million SEK | 6.19% |
| 2023 Q1 | -11.9 Million SEK | 23.06% |
| 2023 Q4 | -12.4 Million SEK | -16.98% |
| 2022 Q3 | -13.3 Million SEK | 4.32% |
| 2022 Q1 | -15.3 Million SEK | 4.96% |
| 2022 Q4 | -15.46 Million SEK | -16.29% |
| 2022 Q2 | -13.9 Million SEK | 9.15% |
| 2022 FY | - SEK | -16.22% |
| 2021 Q2 | -12.7 Million SEK | -30.93% |
| 2021 Q3 | -11.3 Million SEK | 11.02% |
| 2021 FY | - SEK | -56.15% |
| 2021 Q4 | -16.09 Million SEK | -42.47% |
| 2021 Q1 | -9.7 Million SEK | -145.07% |
| 2020 Q1 | -9.7 Million SEK | 9.59% |
| 2020 Q2 | -10.1 Million SEK | -4.12% |
| 2020 Q4 | -3.95 Million SEK | 52.88% |
| 2020 FY | - SEK | 0.89% |
| 2020 Q3 | -8.4 Million SEK | 16.83% |
| 2019 FY | - SEK | -6.7% |
| 2019 Q4 | -10.72 Million SEK | -14.14% |
| 2019 Q2 | -5.7 Million SEK | 48.65% |
| 2019 Q1 | -11.1 Million SEK | -59.46% |
| 2019 Q3 | -9.4 Million SEK | -64.91% |
| 2018 FY | - SEK | -515.46% |
| 2018 Q4 | -6.96 Million SEK | -0.88% |
| 2018 Q1 | -8.5 Million SEK | -6.68% |
| 2018 Q3 | -6.9 Million SEK | 5.48% |
| 2018 Q2 | -7.3 Million SEK | 14.12% |
| 2017 Q3 | -6.5 Million SEK | 71.74% |
| 2017 Q1 | -14.6 Million SEK | -44.58% |
| 2017 Q4 | -7.96 Million SEK | -22.58% |
| 2017 Q2 | -23 Million SEK | -57.53% |
| 2017 FY | - SEK | 116.42% |
| 2016 Q1 | -16.1 Million SEK | 36.18% |
| 2016 Q4 | -10.09 Million SEK | 9.03% |
| 2016 Q3 | -11.1 Million SEK | 23.45% |
| 2016 Q2 | -14.5 Million SEK | 9.94% |
| 2016 FY | - SEK | 74.02% |
| 2015 Q1 | -54.4 Million SEK | -8.32% |
| 2015 FY | - SEK | 23.44% |
| 2015 Q4 | -25.22 Million SEK | -31.39% |
| 2015 Q3 | -19.2 Million SEK | 71.39% |
| 2015 Q2 | -67.1 Million SEK | -23.35% |
| 2014 Q3 | -52.6 Million SEK | 4.19% |
| 2014 Q4 | -50.22 Million SEK | 4.52% |
| 2014 FY | - SEK | -9.79% |
| 2014 Q1 | -56.2 Million SEK | 23.74% |
| 2014 Q2 | -54.9 Million SEK | 2.31% |
| 2013 Q4 | -73.7 Million SEK | -336.22% |
| 2013 FY | - SEK | -28.44% |
| 2013 Q1 | -73.8 Million SEK | -1441.82% |
| 2013 Q3 | 31.2 Million SEK | 140.84% |
| 2013 Q2 | -76.4 Million SEK | -3.52% |
| 2012 Q1 | -100.6 Million SEK | -6.34% |
| 2012 Q4 | 5.5 Million SEK | 111.41% |
| 2012 Q3 | -48.2 Million SEK | -142.21% |
| 2012 Q2 | -19.9 Million SEK | 80.22% |
| 2012 FY | - SEK | -99.48% |
| 2011 FY | - SEK | 66.12% |
| 2011 Q1 | -70.9 Million SEK | 8.4% |
| 2011 Q2 | 141.5 Million SEK | 299.58% |
| 2011 Q3 | -76.8 Million SEK | -154.28% |
| 2011 Q4 | -94.6 Million SEK | -23.18% |
| 2010 Q3 | -47.3 Million SEK | 7.8% |
| 2010 Q2 | -51.3 Million SEK | -0.79% |
| 2010 Q4 | -77.4 Million SEK | -63.64% |
| 2010 Q1 | -50.9 Million SEK | -4.79% |
| 2010 FY | - SEK | -6.49% |
| 2009 Q2 | -54.8 Million SEK | 13.97% |
| 2009 Q1 | -63.7 Million SEK | 0.0% |
| 2009 Q3 | -46.2 Million SEK | 15.69% |
| 2009 FY | - SEK | -15.53% |
| 2009 Q4 | -48.57 Million SEK | -5.14% |
| 2008 FY | - SEK | 8.92% |
| 2007 FY | - SEK | -97.8% |
| 2006 FY | - SEK | 6.15% |
| 2005 FY | - SEK | -153.34% |
| 2004 FY | - SEK | -40.1% |
| 2003 FY | - SEK | -1.4% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alzinova AB (publ) | 41.99 Thousand SEK | 104595.345% |
| Amniotics AB (publ) | -27.14 Million SEK | -61.688% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -208.694% |
| BioArctic AB (publ) | 275.38 Million SEK | 115.936% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 88.068% |
| Saniona AB (publ) | -69.69 Million SEK | 37.03% |
| Simris Alg AB (publ) | -22.36 Million SEK | -96.248% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 86.176% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -124.153% |
| NextCell Pharma AB | -40.98 Million SEK | -7.08% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -156.882% |
| AcouSort AB (publ) | -16.7 Million SEK | -162.749% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 81.53% |
| Camurus AB (publ) | 562.54 Million SEK | 107.802% |
| Cantargia AB (publ) | -284.31 Million SEK | 84.564% |
| Genovis AB (publ.) | 64.57 Million SEK | 167.966% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 61.807% |
| Mendus AB (publ) | -97.84 Million SEK | 55.147% |
| Kancera AB (publ) | -61.88 Million SEK | 29.088% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -63.861% |
| LIDDS AB (publ) | -39.67 Million SEK | -10.63% |
| Lipum AB (publ) | -37.11 Million SEK | -18.233% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -262.583% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 239.75% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2194450.0% |
| OncoZenge AB (publ) | 7.26 Million SEK | 704.005% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 84.439% |
| Xintela AB (publ) | -53.47 Million SEK | 17.924% |
| Ziccum AB (publ) | -20.34 Million SEK | -115.746% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -18.537% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 74.156% |
| CombiGene AB (publ) | -35.33 Million SEK | -24.199% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 68.842% |
| Intervacc AB (publ) | -68.98 Million SEK | 36.377% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2009.952% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -226.759% |
| Corline Biomedical AB | -1.69 Million SEK | -2495.328% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 74.679% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 19.923% |
| Aptahem AB (publ) | -10 Million SEK | -338.465% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 480.007% |
| Fluicell AB (publ) | -25.91 Million SEK | -69.356% |
| Biovica International AB (publ) | -119.5 Million SEK | 63.276% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -3.939% |
| Abliva AB (publ) | -93.6 Million SEK | 53.116% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 86.247% |
| 2cureX AB (publ) | -35.13 Million SEK | -24.906% |
| I-Tech AB | 30.34 Million SEK | 244.627% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 93.858% |
| Cyxone AB (publ) | -20.41 Million SEK | -114.985% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 57.164% |
| Biosergen AB | 228 Thousand SEK | 19348.684% |
| Nanologica AB (publ) | -62.11 Million SEK | 29.35% |
| SynAct Pharma AB | -222.7 Million SEK | 80.293% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -0.059% |
| BioInvent International AB (publ) | -312.7 Million SEK | 85.965% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 14283.955% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 81.052% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -398.01% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 59.573% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -282.658% |